I see that Deejavu did in another post. So I looked it up.
At Bowen Research & Training Institute, Inc., located in Palm Harbor, Florida, ongoing research is being conducted using the Bowen Q-RIBb (Quantitative Rapid Identification of Borrelia burgdorferi) test developed by Dr. JoAnne Whitaker.
Since its inception, the main focus at the institute has been the development of an accurate test for the Borrelia burgdorferi (Bb) antigen, the causative agent of Lyme disease.
According to a clinical study presented at a Lyme Disease Association Conference in 2003, of the tests available, the PCR is only 35% accurate for blood testing, and the Western Blot is only 50 - 60% accurate for blood testing. Other Lyme tests like the LUAT and ELISA fall below these levels of accuracy when testing for Lyme disease.
These tests were originally "... devised to track a narrow band of cases for epidemiologic change and were never set up to be used as diagnostic criteria nor were they meant to define the entire scope of Lyme disease." This is stated in the 3/25/91 NIH report.
Recently, Dr. Whitaker developed the titration serial dilution method for quantitating the amount of Bb antigen in the blood. This may help to differentiate the carriers from the patients with serious disease by comparing persistence of fluorescing structures. In this part of the test, whole blood is diluted and fluorescent antibody added.
The solution containing the antigen is progressively diluted down until a count of the antigen in that particular blood sample remains.
According to a recent poll of patients clinically diagnosed with Lyme disease whose physicians had ordered the Bowen Q-RIBb test, 100% of those patients tested with the Bowen reported their tests were positive for Bb.
Outside critics of the test believe the Bowen has "too many positives." Not so, if you consider that the people taking the Bowen Q-RiBb test could be 'clinically diagnosed' with Lyme just by evaluating their symptoms. Most had received negative or equivocal test results with the other Lyme tests ordered by their physicians.
When negative or equivocal test results are interpreted by their physicians, it is determined that it is unlikely that their patients are infected with the Lyme bacteria.
Physicians are hesitant to 'clinically' diagnose Lyme based on the symptoms alone. Patients pro-actively seeking an answer to their continued symptoms and suffering eventually learn about the Bowen Q-RIBb test.
A positive result with the Bowen test helps these people finally get a proper diagnosis and get properly treated for Lyme disease and co-infections. The Bowen Q-RIBb test just recently received its preliminary US Patent approval. Although
the Bowen Q-RiBb Test is not presently approved by the FDA for Lyme disease; an application for FDA approval is now pending.
Here's the link:
Bowen, Lyme Testing, Stoneybrook, Igenex, Diagnosis, Labcorp, Specialty Labs, Quest Ronald Nahaas
Post Edited (Cat111) : 1/11/2011 6:33:12 AM (GMT-7)